Investigators Take Aim at GBM With a Biomarker-Driven Approach
Efforts are underway to expedite the identification of therapies that offer promise for patients with glioblastoma
Related Articles
LUMINOSITY Data Continue to Highlight Utility of Telisotuzumab Vedotin in c-MET–Overexpressing NSCLC
Jonathan Goldman, MD, discusses the role of telisotuzumab vedotin in c-MET–overexpressing, nonsquamous, EGFR wild-type advanced NSCLC.
FDA Declines to Expand Label for Talazoparib/Enzalutamide in mCRPC
The FDA declined to expand the label for talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer.
Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström Macroglobulinemia
Bexobrutideg was safe and displayed an ORR of 84.2% in relapsed/refractory Waldenström macroglobulinemia.
Retifanlimab Presents a New Treatment Option for Locally Recurrent or Metastatic SCAC
Cathy Eng, MD, FACP, FASCO, highlights the significance of the FDA approval of retifanlimab for managing locally recurrent or metastatic SCAC.
Axi-Cel, Liso-Cel, and Tisa-Cel Show Comparable Real-World Survival Outcomes in DLBCL
Comparable survival outcomes were seen between all 3 FDA-approved CAR T-cell therapies across indications in patients with DLBCL over a 3-year period.
VERONA Trial Misses Primary End Point of OS Benefit With Azacitidine/Venetoclax in Higher-Risk MDS
Venetoclax plus azacitidine did not yield an OS benefit vs placebo plus azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes.
Using Self-Directed Learning to Combat Information Overload in Oncology Fellowship
Jill Gilbert, MD, discusses how principles of adult learning theory can be applied to hematology/oncology fellowship.
Long-Term Remission, OS With Cilta-Cel Sets New Benchmark for Survival Outcomes in R/R Myeloma
Peter Voorhees, MD, highlights 5-year follow-up data from the CARTITUDE-1 trial evaluating cilta-cel in relapsed/refractory multiple myeloma.
FDA Releases CRLs for Previous Drug and Biologic Product Applications
The FDA has published a collection of complete response letters that were seeking the approval of drugs or biologic products between 2020 and 2024.
BGB-16673 Informs Future Direction for BTK Degraders in Relapsed/Refractory CLL/SLL
Lydia Scarfò, MD, details the early efficacy and safety profile of BTK degrader BGB-16673 for the treatment of patients with relapsed/refractory CLL/SLL.